CA2401070A1 - Compositions and methods for diagnosis and therapy of malignant mesothelioma - Google Patents

Compositions and methods for diagnosis and therapy of malignant mesothelioma Download PDF

Info

Publication number
CA2401070A1
CA2401070A1 CA002401070A CA2401070A CA2401070A1 CA 2401070 A1 CA2401070 A1 CA 2401070A1 CA 002401070 A CA002401070 A CA 002401070A CA 2401070 A CA2401070 A CA 2401070A CA 2401070 A1 CA2401070 A1 CA 2401070A1
Authority
CA
Canada
Prior art keywords
seq
peptide
use according
nucleic acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002401070A
Other languages
English (en)
French (fr)
Inventor
Martin A. Cheever
Alexander Gaiger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of CA2401070A1 publication Critical patent/CA2401070A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464452Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453Wilms tumor 1 [WT1]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002401070A 2000-02-22 2001-02-22 Compositions and methods for diagnosis and therapy of malignant mesothelioma Abandoned CA2401070A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18407000P 2000-02-22 2000-02-22
US60/184,070 2000-02-22
PCT/US2001/005702 WO2001062920A2 (en) 2000-02-22 2001-02-22 Compositions and methods for diagnosis and therapy of malignant mesothelioma

Publications (1)

Publication Number Publication Date
CA2401070A1 true CA2401070A1 (en) 2001-08-30

Family

ID=22675440

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002401070A Abandoned CA2401070A1 (en) 2000-02-22 2001-02-22 Compositions and methods for diagnosis and therapy of malignant mesothelioma

Country Status (6)

Country Link
EP (1) EP1261711A2 (de)
JP (1) JP2003524021A (de)
AU (1) AU2001247220A1 (de)
CA (1) CA2401070A1 (de)
NZ (1) NZ521430A (de)
WO (1) WO2001062920A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9912663B8 (pt) 1998-07-31 2021-07-06 Int Inst Cancer Immunology Inc vacina contra cáncer e polipeptìdeo.
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
TWI318630B (en) 2001-03-22 2009-12-21 Int Inst Cancer Immunology Inc Wt1 modified peptide
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
EP1447091A4 (de) * 2001-09-28 2008-02-13 Institute Of Can International Neues verfahren zur induktion von antigen-spezifischen t-zellen
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
ES2378264T3 (es) * 2003-11-05 2012-04-10 International Institute Of Cancer Immunology, Inc. Péptido antigénico de unión a HLA-DR derivado de WT1
US7488718B2 (en) 2003-12-01 2009-02-10 Sloan Kettering Institue For Cancer Research Synthetic HLA binding peptide analogues and uses thereof
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1951281B1 (de) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla klasse ii-bindungspeptide und diese umfassende zusammensetzungen und verfahren
EP1790664A1 (de) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
EP3117836A1 (de) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogene wt-1-peptide und verwendungen davon
DK2341142T3 (en) * 2006-12-28 2014-12-08 Int Inst Cancer Immunology Inc HLA-A * 1101-restricted WT1 peptide or pharmaceutical composition comprising this
CN103103246B (zh) 2007-02-27 2018-05-01 株式会社癌免疫研究所 活化辅助t细胞的方法以及用于该方法的组合物
WO2012046730A1 (ja) 2010-10-05 2012-04-12 国立大学法人大阪大学 ヘルパーt細胞の活性化方法
CN104684577B (zh) * 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
CA2890438C (en) 2012-11-13 2022-10-18 Biontech Ag Agents for treatment of claudin expressing cancer diseases
EP2933261B1 (de) 2012-12-17 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Verfahren zur aktivierung von t-helferzellen
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CA2840988A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for mucosal administration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9912663B8 (pt) * 1998-07-31 2021-07-06 Int Inst Cancer Immunology Inc vacina contra cáncer e polipeptìdeo.
MY139226A (en) * 1998-09-30 2009-08-28 Corixa Corp Compositions and methods for wt1 specific immunotherapy

Also Published As

Publication number Publication date
WO2001062920A2 (en) 2001-08-30
AU2001247220A1 (en) 2001-09-03
WO2001062920A3 (en) 2002-07-18
JP2003524021A (ja) 2003-08-12
EP1261711A2 (de) 2002-12-04
NZ521430A (en) 2004-04-30

Similar Documents

Publication Publication Date Title
CA2401070A1 (en) Compositions and methods for diagnosis and therapy of malignant mesothelioma
JP4130359B2 (ja) Wt1特異的免疫療法のための組成物および方法
US8071732B2 (en) Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
CA2465303C (en) Compositions and methods for wt1 specific immunotherapy
AU2002367594B2 (en) Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20020193329A1 (en) Compositions and methods for the therapy and diagnosis of Her-2/neu-associated malignancies
CZ2003537A3 (cs) Izolovaný polynukleotid
US7323181B2 (en) Compositions and methods for WT1 specific immunotherapy
WO2002013847A2 (en) Methods for diagnosis and therapy of hematological and virus-associated malignancies
JP2004520802A (ja) 乳癌の治療および診断のための組成物および方法
CA2383615A1 (en) Methods for diagnosis and therapy of hematological and virus-associated malignancies
WO2001064886A2 (en) Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20020150588A1 (en) SPAS-1 cancer antigen
US20030082194A1 (en) Compositions and methods for diagnosis and therapy of malignant mesothelioma
CZ20024213A3 (cs) Prostředky a způsoby léčení a diagnostiky rakoviny prsu
US20180105562A1 (en) Immune modulator for immunotherapy and vaccine formulation
US20040175739A1 (en) Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20020058292A1 (en) Ovarian tumor antigen and methods of use therefor
US20020155468A1 (en) Ovarian tumor antigen and methods of use therefor
US7241876B2 (en) Compositions and methods for the therapy and diagnosis of breast cancer
US7704701B2 (en) Diagnosis of prostate cancer with SPAS-1 cancer antigen
US20020064815A1 (en) Ovarian tumor antigen and methods of use therefor
US20030157119A1 (en) Methods for diagnosis and therapy of hematological and virus-associated malignancies

Legal Events

Date Code Title Description
FZDE Discontinued